ENTX Entera Bio Ltd.
USHealthcareAs of 2026-07-10 16:00
Why ENTX matters now
Entera Bio Ltd. (ENTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.66 with -2.65% on the session and $81.6M in market capitalization; recent performance reads 1-month -4.72% and YTD -37.63%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.5M, and EPS of $-0.07. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -16.1%.
The latest indexable market news headline is "Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Burshtein Gregory filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.41
P/S
0.00
EV/EBITDA
-4.53
DCF Value
$0.14
FCF Yield
-16.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-88.0%
ROA
-94.3%
ROIC
-106.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.5M | $-0.07 |
| Q4 2025 | $0.00 | $-3.0M | $-0.07 |
| FY 2025 | $42.0K | $-11.4M | $-0.25 |
| Q3 2025 | $0.00 | $-3.2M | $-0.07 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
1.49
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.